Reduced placental growth and hCG secretion in vitro induced by antiphospholipid antibodies but not by anti-Ro or anti-La: studies on sera from women with SLE/PAPS
Restricted accessResearch articleFirst published online February, 2007
Reduced placental growth and hCG secretion in vitro induced by antiphospholipid antibodies but not by anti-Ro or anti-La: studies on sera from women with SLE/PAPS
Systemic lupus erythematosus (SLE) and primary anti-phospholipid syndrome (PAPS) are autoimmune diseases causing recurrent pregnancy loss. We hypothesized that anti-phospholipid antibodies (aPL), but not anti-Ro and anti-La antibodies, might have a role through direct placental damage. We cultured human placental explants in sera from women with SLE/PAPS with different antibodies. These sera were found to reduce placental growth and increase trophoblastic apoptosis. No effect was found on estradiol or progesterone secretion, but inhibition in βhCG secretion was detected. βhCG was reduced in women with a history of recurrent pregnancy loss or thromboembolic events, and was also the most sensitive marker when examining the effects of specific antibodies. High titers of aPL were found to cause the largest reduction in βhCG. Anti-Ro and anti-La did not induce placental damage. A strong correlation was found between the rise in the number of different antibodies in the sera and the incidence of recurrent pregnancy loss, which was also accompanied by a decline in the βhCG levels. In conclusion, aPL, but not anti-Ro or anti-La, may cause placental damage in vitro. Thus βhCG levels might constitute a predictive marker for the risk of placental damage and pregnancy loss in women with SLE/PAPS.
Ornoy A, Chen L, Silver RM, Miller RK. Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damage. Birth Defects Res A Clin Mol Teratol2004; 70: 371–381.
2.
Schur PH, Bermas BL. Pregnancy in women with systemic lupus erythematosus. Available from www.uptodate.com, 2005.
3.
George NT. APA and the antiphospholipid antibody syndrome. Am J Dermatology1997; 36: 149–163.
4.
Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med2002; 346: 752–763.
5.
Abramowsky CR, Vegas ME, Swinehart G, Gyves MT. Decidual vasculopathy of the placenta in systemic lupus erythematosus. N Engl J Med1980; 303: 668–672.
6.
Katsuragawa H, Rote NS, Inoue T, Narukawa S, Kanzaki H, Mori T. Monoclonal antiphosphatidylserine antibody reactivity against human first-trimester placental trophoblasts. Am J Obstet Gynecol1995; 172: 1592–1597.
7.
Abir R, Ornoy A. Teratogenic IgG from sera of women with spontaneous abortions seem to induce anomalies and yolk sac damage in rat embryos. A possible method to detect abortions of immunologic origin. Am J Reprod Immun1996; 35: 93–101.
8.
Ornoy A, Yacobi S, Avraham S, Blumenfeld Z. The effect of sera from women with systemic lupus erythematosus and/or antiphospholipid syndrome on rat embryos in culture. Reprod Toxicol1998; 12: 185–191.
9.
Yacobi S, Ornoy A, Blumenfeld Z, Miller RK. Effect of sera from women with systemic lupus erythematosus or antiphospholipid syndrome and recurrent abortions on human placental explants in culture. Teratology2002; 66: 300–308.
10.
Genbacev O, Miller RK. Three-dimensional culture of placental villous tissue explants: an in vitro model for periimplantation. Methods in Toxicology1993; 3B: 246–265.
11.
Genbacev O, Miller RK. Post-implantation differentiation and proliferation of cytotrophoblast cells: in vitro models – a review. Placenta2000; 21(Suppl. A): S45–S49.
12.
To CH, Petri M. Is antibody clustering predictive of clinical subsets and damage in systemic lupus erythematosus?Arthritis Rheum2005; 52: 4003–4010.
13.
Bermas BL, Schur PH. Pathogenesis of the antiphospholipid syndrome. Available from www.uptodate.com, 2005.
14.
Sailer T, Zoghlami C, Kurz C et al. Anti-beta2-glycoprotein I antibodies are associated with pregnancy loss in women with the lupus anticoagulant. Thromb Haemost2006; 95: 796–801.
15.
Blank M, Cohen J, Toder V, Shoenfeld Y. Induction of anti-phospholipid syndrome by passive transfer of anti-cardiolipin antibodies. Proc Nat Acad Sci1991; 88: 3069–3073.
16.
George J, Blank M, Levy Y et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation1998; 97: 900–906.
17.
Blank M, Shoenfeld Y, Cabilly S, Heldman Y, Fridkin M, Katchalski-Katzir E. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci (USA)1999; 96: 5164–5168.
18.
Ieko M, Nakabayashi T, Tarumi T et al. Phosphatidylserine-dependent anti-prothrombin antibody as a new marker for the diagnosis of antiphospholipid syndrome. Rinsho Byori2006; 54: 256–262.
19.
Lopez LR, Dier KJ, Lopez D, Merrill JT, Fink CA. Anti-beta 2-glyco-protein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol2004; 121: 142–149.
20.
Toschi V, Motta A, Castelli C et al. Prevalence and clinical significance of aPL to noncardiolipin antigens in systemic lupus erythematosus. Haemostasis1993; 23: 275–283.
21.
Balada E, Ordi-Ros J, Paredes F, Villarreal J, Mauri M, Vilardell-Tarres M. Antiphosphatidylethanolamine antibodies contribute to the diagnosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. Scand J Rheumatol2001; 30: 235–241.
22.
Karmochkine M, Berard M, Piette JC et al. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus1993; 2: 157–160.
23.
Reichlin M. Clinical significance of anti-Ro/SSA and anti-La/SSB anti-bodies. Available from www.uptodate.com, 2005.
24.
Watson RM, Braunstein BL, Watson AJ, Hochberg MC, Provost TT. Fetal wastage in women with anti-Ro/SSa antibody. The Journal of Rheumatology1986; 13: 90–94.
25.
Mavragani CP, Dafni UG, Tzioufas AG, Moutsopoulos HM. Pregnancy outcome and anti-Ro/SSA in autoimmune diseases: a retrospective cohort study. British J Rheumatol1998; 37: 740–745.
26.
Brucato A, Doria A, Frassi M et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus2002; 11: 716–721.
27.
Blank M, Faden D, Tincani A et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun1994; 7: 441–455.
28.
Qureshi F,Yang Y, Jaques SM et al. Anti-DNA antibodies cross-reacting with laminin inhibit trophoblast attachment and migration: implications for recurrent pregnancy loss in SLE patients. Am J Reprod Immunol2000; 44: 136–142.
29.
Sakui H,Yoshimura Y, Tada S et al. Serological and immunohistochemical studies in pregnant women with systemic lupus erythematosus. Nippon Sanka Fujinka Gakkai Zasshi1989; 41: 249–256.
30.
Salmon JE, Girardi G, Holers VM. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus2003; 12: 535–538.
31.
Hanly JG, Gladman DD, Rose TH, Laskin CA, Urowitz MB. Lupus pregnancy. A prospective study of placental changes. Arthritis rheum1988; 31: 358–366.
32.
Rull K, Laan M. Expression of beta-subunit of HCG genes during normal and failed pregnancy. Hum Reprod2005; 20: 3360–3368.
33.
Bahado-Singh RO, Oz AU, Kingston JM, Shahabi S, Hsu CD, Cole L. The role of hyperglycosylated hCG in trophoblast invasion and the prediction of subsequent pre-eclampsia. Prenat Diagn2002; 22: 478–481.
34.
Shi QJ, Lei ZM, Rao CV, Lin J. Novel role of human chorionic gonadotropin in differentiation of human cytotrophoblasts. Endocrinology1993; 132: 1387–1395.
35.
Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal antibody against antiphosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion. Biol Reprod1997; 56: 5650–5658.
36.
Shurtz-Swirski R, Inbar O, Blank M, Cohen J, Bakimer R, Shoenfeld Y. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Amer J Reproduc Immunol1993; 29: 206–210.
